AzTrials
AzTrials

Procedural SedationRIDEXNCT06203522

Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin

An observational study of Procedural Sedation and EEG, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a retrospective cohort study aiming to determine whether the use of Dexmedetomidine (DEX) to sedate children prior to MRI scanning is more or less effective in children with autism spectrum disorders or other neurodevelopmental disorders compared to other children. Read more about this study

Who is it for?
Ages 3 months to 18 years
Conditions the study is for
Procedural Sedation, EEG, MRI
What is being tested?
Data collection of successful completion of MRI
Type of treatment
Surgery or procedure
How many people
81 participants
Where
1 siteFrance
Study dates
1 Jan 2024to 30 Mar 2024
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months to 18 years
  • All sexes
  • Child, Adult

Study population: patients under 18 years of age sedated with DEX IN prior to MRI.

Who may be able to join

  • patients under 18 years of age sedated with DEX IN prior to MRI.

Who cannot join

  • incomplete or missing medical records

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHR Metz-Thionville/Hopital Mercy

    Metz, 57085

Other trials in France

About this study

Official title: Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin: an Observational Study

This is a retrospective cohort study aiming to determine whether the use of Dexmedetomidine (DEX) to sedate children prior to MRI scanning is more or less effective in children with autism spectrum disorders or other neurodevelopmental disorders compared to other children.

Read the detailed description

Performing brain MRI on children under 5, or in cases of autism or disability, is often complex. In fact, this examination requires total immobilization of the child for at least 20 minutes. The noise and the fact that the child is lying in a sort of tunnel add to the child's stress.

General anesthesia with propofol is widely used in France, but requires invasive orotracheal intubation or mask ventilation. There are no national or international recommendations for pediatric MRI sedation procedures.

Intranasal dexmedetomidine (DEX) is used for brain MRI, cardiac ultrasound, ophthalmology, dental treatment and brain computed tomography (CT) in patients aged 3 months to 12 years. Its superior efficacy has been demonstrated in a number of studies compared with the most commonly used medicated procedural sedation techniques, but only one study in France has prospectively analyzed the efficacy of DEX IN for performing cerebral MRIs, but without assessing efficacy and tolerance in subgroups of children: with or without neurodevelopmental disorders, epilepsy, autism, age.

Being tested
Data collection of successful completion of MRI
Keywords
Dexmedetomidin, procedural sedation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Data collection of successful completion of MRIProcedure or surgery

    age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure

Study groups in NCT06203522
Study groupRoleWhat they receive
MRI with DexmedetomidinMean age is compared between the "pass" and "fail" groups using a Student's t-test accounting for inequality of variances. MRI success rates are compared between subgroups using Fischer's exact tests. Finally, factors related to MRI success rates are investigated using multivariate logistic regression, including all the factors described above.
Receives: Procedure: Data collection of successful completion of MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Successful Completion of MRI, defined as the radiologist having no reservations about the interpretation of the images.

    Successful Completion of MRI, defined as the radiologist having no reservations about the interpretation of the images (yes/no)

    Measured: Immediately after procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2024
  2. Study start1 Jan 2024
  3. Primary completion30 Mar 2024
  4. Study completion30 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
81 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06203522
Sponsor's protocol ID
2023-12'Obs-CHRMT
Acronym
RIDEX
Status last verified
Aug 2024
First submitted
3 Jan 2024
Last updated
9 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: According to the French law and the French Data Protection Authority (CNIL), it is not possible to share publicly individual participant data, but only their conclusions through peer-reviewed publications and conferences.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in